FDA OKs Zogenix drug for rare childhood epilepsy

Zogenix (NASDAQ:ZGNX) says the Food and Drug Administration approved its Fintepla drug to treat seizures associated with Dravet syndrome, a rare form of childhood epilepsy.

Fintepla uses a low-dose liquid solution of fenfluramine, which was used in an obesity drug combination that was later withdrawn from the market due to evidence of heart valve damage.

The drug’s main competition will come from GW Pharmaceuticals’ (NASDAQ:GWPH) cannabis-based Epidiolex, which also is approved to treat seizures related to Dravet Syndrome and Lennox-Gastaut syndrome.

Fintepla is expected to bring in peak sales of ~$450M in 5-7 years for its use against Dravet syndrome, Guggenheim analyst Yatin Suneja says.

https://seekingalpha.com/news/3586377-fda-oks-zogenix-drug-for-rare-childhood-epilepsy